Table 1:
Demographic information of the patients and tumor samples across DFCI, MSK, and VICC.
| DFCI | MSK | VICC | DFCI CUP | ||
|---|---|---|---|---|---|
|
| |||||
| Number of patients | 18,106 | 15,151 | 1,310 | 962 | |
| Patients age at sequence (95 % C.I.) | 60.7 (60.5 – 60.9) | 60.2 (60.0 – 60.4) | 58.3 (57.6 – 59.0) | 61.9 (61.1 – 62.7) | |
| Sex; male-female ratio | 43.8 – 56.2 | 43.5 – 56.5 | 44.5 – 55.5 | 50.0 – 50.0 | |
|
| |||||
| Patients ethnicity (proportion %) | |||||
|
| |||||
| White | 16,105 (88.9 %) | 11,575 (76.4 %) | 1,089 (83.1 %) | 853 (88.7 %) | |
| Black | 538 (3.0 %) | 866 (5.7 %) | 72 (5.5 %) | 38 (4.0 %) | |
| Asian | 554 (3.1 %) | 956 (6.3 %) | 17 (1.3 %) | 34 (3.5 %) | |
| Hispanic | 379 (2.1 %) | 744 (4.9 %) | 14 (1.1 %) | 15 (1.6 %) | |
| Others | 530 (2.9 %) | 1010 (6.7 %) | 118 (9.0 %) | 22 (2.2 %) | |
|
| |||||
| Sequenced Tumor Samples | |||||
|
| |||||
| Total number of samples | 18,816 | 16,294 | 1,335 | 971 | |
|
| |||||
| Panel version (proportion %; 95% sequence date range) | |||||
|
| |||||
| v1 | OncoPanel v1 1,924 (10.2 %; 2013–8–20 – 2014–8–17) | MSK-IMPACT341 1,803 (11.1 %; Not available) | VICC-01-T5A 307 (23.0 %; Not available) | OncoPanel v1 47 (4.8 %; 2013–9–8 – 2014–8–12) | |
| v2 | OncoPanel v2 5,304 (28.2 %; 2014–9–28 – 2016–10–5) | MSK-IMPACT410 6,917 (42.5 %; Not available) | VICC-01-T7 1,028 (77.0 %; Not available) | OncoPanel v2 203 (20.9 %; 2014–11–5 – 2016–10–5) | |
| v3 | OncoPanel v3 11,588 (61.6 %; 2016–11–11 – 2021–1–6) | MSK-IMPACT468 7,574 (46.5 %; Not available) | OncoPanel v3 721 (74.3 %; 2016–12–14 – 2020–12–23) | ||
|
| |||||
| Biopsy site type | |||||
|
| |||||
| Primary | 11,662 (62.0 %) | 9,576 (58.8 %) | 622 (46.6 %) | ||
| Metastatic recurrence | 5,737 (30.5 %) | 6,718 (41.2 %) | 637 (47.7 %) | ||
| Local recurrence | 673 (3.6 %) | Not available | 64 (4.8 %) | ||
| Unspecified/others | 744 (4.0 %) | Not available | 12 (0.9 %) | ||
|
| |||||
| Cancer group | Cancer type | Predicted cancer type | |||
|
| |||||
| Lung (Thoracic) | Non-Small Cell Lung Cancer (NSCLC) | 3,489 (18.5 %) | 3,183 (19.5 %) | 137 (10.3 %) | 280 (28.8 %) |
| Pleural Mesothelioma (PLMESO) | 258 (1.4 %) | 118 (0.7 %) | 2 (0.1 %) | 9 (0.9 %) | |
|
| |||||
| Invasive Breast Carcinoma (BRCA) | 2,558 (13.6 %) | 3,113 (19.1 %) | 274 (20.5 %) | 85 (8.8 %) | |
|
| |||||
| Colorectal Adenocarcinoma (COADREAD) | 2,525 (13.4 %) | 1,919 (11.8 %) | 232 (17.4 %) | 63 (6.5 %) | |
|
| |||||
| Upper Gastrointestinal | Esophagogastric Adenocarcinoma (EGC) | 988 (5.3 %) | 495 (3.0 %) | 59 (4.4 %) | 69 (7.1 %) |
| Pancreatic Adenocarcinoma (PAAD) | 772 (4.1 %) | 980 (6.0 %) | 53 (4.0 %) | 85 (8.8 %) | |
| Cholangiocarcinoma (CHOL) | 241 (1.3 %) | 338 (2.1 %) | 44 (3.3 %) | 33 (3.4 %) | |
|
| |||||
| Neuro | Diffuse Glioma (DIFG) | 2,041 (10.8 %) | 1,069 (6.6 %) | 47 (3.5 %) | 25 (2.6 %) |
| Meningothelial Tumor (MNGT) | 179 (1.0 %) | 42 (0.3 %) | 15 (1.1 %) | 4 (0.4 %) | |
|
| |||||
| Gynecologic | Ovarian Epithelial Tumor (OVT) | 1,213 (6.4 %) | 525 (3.2 %) | 81 (6.1 %) | 58 (6.0 %) |
| Endometrial Carcinoma (UCEC) | 703 (3.7 %) | 703 (4.3 %) | 34 (2.5 %) | 18 (1.9 %) | |
|
| |||||
| Urothelial | Renal Cell Carcinoma (RCC) | 457 (2.4 %) | 497 (3.1 %) | 39 (2.9 %) | 24 (2.5 %) |
| Bladder Urothelial Carcinoma (BLCA) | 550 (2.9 %) | 505 (3.1 %) | 41 (3.1 %) | 21 (2.2 %) | |
|
| |||||
| Prostate Adenocarcinoma (PRAD) | 601 (3.2 %) | 1,222 (7.5 %) | 27 (2.0 %) | 27 (2.8 %) | |
|
| |||||
| Melanoma (MEL) | 729 (3.9 %) | 619 (3.8 %) | 187 (14.0 %) | 43 (4.4 %) | |
|
| |||||
| Head and Neck | Head and Neck Squamous Cell Carcinoma (HNSCC) | 473 (2.5 %) | 285 (1.7 %) | 20 (1.5 %) | 52 (5.4 %) |
| Well-Differentiated Thyroid Cancer (WDTC) | 166 (0.9 %) | 166 (1.0 %) | 8 (0.6 %) | 1 (0.1 %) | |
|
| |||||
| Neuroendocrine | Gastrointestinal Neuroendocrine Tumors (GINET) | 219 (1.2 %) | 76 (0.5 %) | 18 (1.3 %) | 46 (4.7 %) |
| Pancreatic Neuroendocrine Tumor (PANET) | 121 (0.6 %) | 133 (0.8 %) | 12 (0.9 %) | 23 (2.4 %) | |
|
| |||||
| Gastrointestinal Stromal Tumor (GIST) | 273 (1.5 %) | 217 (1.3 %) | 5 (0.4 %) | 3 (0.3 %) | |
|
| |||||
| Hematologic | Acute Myeloid Leukemia (AML) | 150 (0.8 %) | 1 (0.0 %) | 0 (0.0 %) | 1 (0.1 %) |
| Non-Hodgkin Lymphoma (NHL) | 110 (0.6 %) | 88 (0.5 %) | 0 (0.0 %) | 1 (0.1 %) | |